Subsequent treatment for locally advanced non-small-cell lung cancer that progressed after definitive chemoradiotherapy and consolidation therapy with durvalumab: a multicenter retrospective analysis (TOPGAN 2021-02).
Tsukasa HasegawaRyo AriyasuHisashi TanakaRyota SaitoYosuke KawashimaAtsushi HoriikeToshio SakataniTakehiro TozukaJun ShiiharaMasafumi SaikiYuichi TamboTomoaki SonodaAkito MiyazakiShinya UematsuYuko Tsuchiya-KawanoNoriko YanagitaniMakoto NishinoPublished in: Cancer chemotherapy and pharmacology (2023)
In patients with LA-NSCLC hat progressed after definitive CRT and durvalumab consolidation therapy, subsequent treatment may change depending on the timing of disease progression.